A detailed history of Hancock Whitney Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hancock Whitney Corp holds 319,008 shares of BMY stock, worth $18.3 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
319,008
Previous 24,291 1213.28%
Holding current value
$18.3 Million
Previous $1.01 Million 1537.7%
% of portfolio
0.54%
Previous 0.03%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $11.7 Million - $15.3 Million
294,717 Added 1213.28%
319,008 $16.5 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $10,626 - $13,989
-264 Reduced 1.08%
24,291 $1.01 Million
Q1 2024

May 16, 2024

BUY
$47.98 - $54.4 $65,492 - $74,256
1,365 Added 5.89%
24,555 $1.33 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $193,435 - $230,821
-3,990 Reduced 14.68%
23,190 $1.19 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $39,423 - $44,081
-681 Reduced 2.44%
27,180 $1.58 Million
Q2 2023

Nov 13, 2023

BUY
$63.71 - $70.74 $75,432 - $83,756
1,184 Added 4.44%
27,861 $1.78 Million
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $75,432 - $83,756
1,184 Added 4.44%
27,861 $1.78 Million
Q1 2023

Nov 13, 2023

BUY
$65.71 - $74.53 $88,379 - $100,242
1,345 Added 5.31%
26,677 $1.85 Million
Q1 2023

May 16, 2023

BUY
$65.71 - $74.53 $88,379 - $100,242
1,345 Added 5.31%
26,677 $1.85 Million
Q4 2022

Nov 13, 2023

SELL
$68.48 - $81.09 $173,185 - $205,076
-2,529 Reduced 9.08%
25,332 $1.82 Million
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $129,221 - $153,016
-1,887 Reduced 6.93%
25,332 $1.82 Million
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $4 - $2,612
-34 Reduced 0.12%
27,219 $1.94 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $24,255 - $26,713
334 Added 1.24%
27,253 $2.1 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $10,021 - $12,016
163 Added 0.61%
26,919 $1.97 Million
Q4 2021

Jan 25, 2022

SELL
$53.63 - $62.52 $10,672 - $12,441
-199 Reduced 0.74%
26,756 $1.67 Million
Q3 2021

Nov 04, 2021

SELL
$59.17 - $69.31 $74,021 - $86,706
-1,251 Reduced 4.44%
26,955 $1.6 Million
Q2 2021

Aug 09, 2021

SELL
$61.91 - $67.42 $104,751 - $114,074
-1,692 Reduced 5.66%
28,206 $1.89 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $231,544 - $260,419
-3,902 Reduced 11.54%
29,898 $1.89 Million
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $44,171 - $50,053
-765 Reduced 2.21%
33,800 $2.1 Million
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $53,811 - $59,630
-937 Reduced 2.64%
34,565 $2.08 Million
Q2 2020

Jul 30, 2020

BUY
$54.82 - $64.09 $476,659 - $557,262
8,695 Added 32.44%
35,502 $2.09 Million
Q1 2020

May 08, 2020

SELL
$46.4 - $67.43 $956,536 - $1.39 Million
-20,615 Reduced 43.47%
26,807 $1.5 Million
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $310,416 - $404,910
6,308 Added 15.34%
47,422 $3.04 Million
Q3 2019

Oct 29, 2019

BUY
$42.77 - $50.71 $714,087 - $846,654
16,696 Added 68.38%
41,114 $2.08 Million
Q2 2019

Aug 29, 2019

SELL
$44.62 - $49.34 $88,258 - $97,594
-1,978 Reduced 7.49%
24,418 $1.11 Million
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $402,741 - $480,218
-8,926 Reduced 25.27%
26,396 $1.26 Million
Q4 2018

Feb 15, 2019

BUY
$48.76 - $63.23 $127,507 - $165,346
2,615 Added 8.0%
35,322 $1.84 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $564,483 - $636,693
10,228 Added 45.5%
32,707 $2.03 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $757 - $944
15 Added 0.07%
22,479 $1.24 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $50,332 - $57,943
840 Added 3.88%
22,464 $1.42 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $853,665 - $930,714
14,242 Added 192.93%
21,624 $1.33 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $49,707 - $57,366
-900 Reduced 10.87%
7,382 $471,000
Q2 2017

Aug 11, 2017

BUY
N/A
8,282
8,282 $462,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hancock Whitney Corp Portfolio

Follow Hancock Whitney Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.